Eupraxia Pharmaceuticals vs Rani Therapeutics
EPRX and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EPRX and RANI compare
Eupraxia Pharmaceuticals scores higher on the StockData Score (5 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EPRX | RANI |
|---|---|---|
| Size and price | ||
| Market cap | – | $73.4M |
| Share price | $8.15 | $0.526 |
| Change, 1 year | 23.5% | −75.2% |
| Change, 5 years | 254% | −98.5% |
| Beta (5Y) | −0.02 | 0.85 |
| Employees | – | 69 |
| StockData Score | ||
| Total score | 5 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.1× |
| P/B | – | 2.2× |
| FCF yield | – | −31.7% |
| Fair value | – | $0.366 |
| Margin of safety | – | −43.8% |
| Growth | ||
| Revenue growth (TTM) | – | 449% |
| Revenue growth, 5Y average | – | 28.7% |
| Profitability | ||
| Operating margin | – | −530% |
| Net margin | – | −493% |
| FCF margin | – | −353% |
| Return on equity | −66.8% (better) | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −71.9× |
| Current ratio | 15.12 (better) | 5.26 |
| Altman Z-score | – | −1.36 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 41.1% | 32.7% |
| Held by insiders | 9.7% | 30.6% |
| Insider net buying, 12 months | – | $49.7K |
| Short interest, % of float | 11.5% | 8.5% |
Go deeper
- EPRX stock overview
- EPRX income statement
- EPRX valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.